Instruction for Authors

1. Aims and Scope

*Archives of Pharmacal Research* is an interdisciplinary journal devoted to the publication of original research papers and reviews in the fields of drug discovery, drug development, and drug actions with a view of providing fundamental and novel information on drugs and drug candidates.

Manuscripts will be considered for publication on the condition that the results reported are based on original research that has not been published elsewhere in any journal.

Upon acceptance of an article for publication in *Archives of Pharmacal Research*, the author tacitly agrees to make available any materials used in the published experiments, or any novel or natural product disclosed in the article that are not commercially available, so that other researchers may confirm the observations.

For the studies using natural extract, the journal will determine the acceptability of such papers on an individual basis. Natural product contribution must meet the following specific criteria: a) any natural extract must be defined, and appropriate information must be provided regarding its origin; b) the author must be able to state that the material under study is endotoxin free.

2. Types of Papers

*Archives of Pharmacal Research* considers manuscripts for publication in the following types of papers:

**Original Research Articles.** These are full-length descriptions of research that describe original and important pieces of work in detail from the fields covered by the journal. Maximum length of manuscripts should not exceed 6,000 words excluding figures and tables.

**Review Articles.** Review articles on various topics are welcome. Both invited and unsolicited submissions are published. Authors may submit a short synopsis to editors (pskor@korea.com) regarding content and length prior to submission. At least 3 figures or tables (in total) should be included (for review). Please note that reviews will be subjected to appropriate evaluation process.

**Report on Investigational Drugs.** We have created a new section called ‘Report on Investigational Drugs,’ to cover recent updates in the field of drug development and discovery. The report should describe recent trends in new drug development among pharmaceutical and bio-venture companies, research institutes and universities. A focused report on one particular drug would be recommended. The report should contain a brief background, a description of drug candidate (e.g., effects and relevant experimental data) and its prospective view. The total length should be about 1000 words excluding references.

3. How to Submit Manuscripts

All submissions should be made online at the *Archives of Pharmacal Research* Editorial Manager site at www.editorialmanager.com/arpr. New users will first need to register. Once logged on to the site as an author, follow the instructions to submit your manuscript. Authors should submit the text, tables and artworks in electronic form via this web-based manuscript submission system.

Authors must include a cover letter that contains a brief outline of the work’s originality, that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out.

**Submission Checklist:**

- Letter of submission (cover letter)
- Title page which includes the number of words in the text from Abstract to Discussion and the number of tables, figures, and references.
- Manuscript organization guideline.
- Manuscript that is double-spaced and organized throughout including references, figure legends, and tables.
- High-resolution digital images.
- References checked for accuracy.

**English Language Editing:** Prior to submission, it is encouraged to use a professional language-editing service for non-English speaking authors who would like to refine their language use in the manuscripts.

Upon the acceptance of the manuscript after reviewing process, the *Archives of Pharmacal Research* will charge a publication fee of US $20 per printed page and a submission fee of US $100.

4. Preparation of Manuscripts

Manuscripts should be in English, typewritten using Arial or Times New Roman fonts (12-point size) only, and double-spaced throughout on A-4 size with at least 2.5 cm margin. Original articles should contain the following sections in the orders listed. Each section should begin on a new page and all pages should be numbered consecutively.

1) **Title Page.** This should contain the complete title of the article, the names of all authors, the affiliation of authors, a running title of no more than 50 characters including spaces, and mailing address, which includes telephone and fax numbers and e-mail address of the corresponding author. Place an asterisk after the name of the corresponding author. Author affiliations must be footnoted using superscript numbers. The title should be a brief phrase, not a complete sentence, describing the contents of the manuscript. Symbols, formulas, or arbitrary abbreviations should not be included in the title, except chemical symbols to indicate the structure of isotopically labeled compounds.

The number of words in the text from Abstract to Discussion and the number of tables, figures, and references should be contained in the title page.

2) **Abstract.** The abstract should concisely present the hypothesis being tested, general methods, results, and
conclusions. Abstracts of more than 200 words will not be accepted. A word is one or more characters bounded by white space. The abstract must be a single paragraph. Four to six keywords should be supplied following the abstract.

3) Introduction. This section must contain a clear statement of the aims of the work or of the hypotheses being tested. A brief account of the relevant background that supports the rationale of the study should also be given. The length of the Introduction should not exceed 750 words. No attempt should be made to indicate the results obtained.

4) Materials and Methods. Procedures used in the work should be given in sufficient detail to permit the repetition by other researchers. Nevertheless, published procedures should be briefly summarized by mentioning the reference(s) and only described in detail if the procedures have been modified. The name of manufacturer should be specified without address (include only city and country).

All human and animal studies must have been approved by the author’s institutional review board and the name of the review board should be stated. All clinical investigation must have been conducted according to Declaration of Helsinki principles. For the policies on the research and publication ethics not stated, ‘Good Publication Practice Guidelines for Medical Journals (http://kamje.or.kr/publishing_ethics.html)’ or ‘Guidelines on good publication (http://www.publicationethics.org.uk/guidelines) can be applied.

5) Results. In this section, only observations should be described without discussion of their significance. Results are typically presented in figures or tables, with no duplication of information in the text.

If possible, statistical significance of the experimental data should be provided. Statistical probability (p) in tables, figures, figure legends and text should be expressed as *p < 0.05, **p < 0.01, and ***p < 0.001. For multiple comparisons within a table, footnotes italicized in lower case with superscript letters should be used and defined in the table legend. References to statistical methods of calculation should be provided. If statistical limits cannot be provided, the number of determinations and some indication of the variability and reliability of the results should be provided. For animal experimental data, doses and concentrations should be expressed as molar quantities (e.g., mmol/kg, mM) when comparisons are made between compounds having large differences in molecular weights. The routes of administration of test compounds and vehicles used should be indicated.

6) Discussion. Discussion should be provided separately from the Results. Whereas speculative discussion is allowed, it must be identified as such and be based on the data presented. Conclusions drawn from the results presented are included in this section. The Discussion must be as concise as possible and should not exceed 1,500 words.

7) Conflict of Interest. All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work.

8) Acknowledgements. The Acknowledgment section should include credits [last name and initial(s)] for technical assistance, financial support, and other appropriate recognition.

9) References Citation
Cite references in the text by name and year in parentheses. Some examples:

- Negotiation research spans many disciplines (Thompson 1990).
- This result was later contradicted by Becker and Seligman (1996).
- This effect has been widely studied (Abbott 1991; Nottin 1995; Nottin et al. 1998; Seligman et al. 1999).

Reference list
The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a reference list.

Reference list entries should be alphabetized by the last names of the first author of each work. Also, the names of all authors should be provided.

- Journal article
- Article by DOI
- Book
- Book chapter
- Online document
- Dissertation
  Trent JW (1975) Experimental acute renal failure. Dissertation, University of California

Always use the standard abbreviation of a journal’s name according to the ISSN List of Title Word Abbreviations, see http://www.issn.org/services/online-services/access-to-the-ltwa/. If you are unsure, please use the full journal title.
10) Tables. These should be numbered consecutively with Arabic numerals in the order cited in the text. Tables should be formatted with horizontal lines only; vertical ruled lines are not required. Footnotes in tables should be given lowercase letter designations and be cited in the table by italic superscript letters. Each table must be double-spaced and begin on a separate page. Each table should be provided with a descriptive heading, which, together with the individual column headings, should make the table, as nearly as possible, self-explanatory. In setting up tabulations, tables need to fit the type area of the journal page (17.8 × 25.4 cm) and the column width (8.5 cm). Arrangements that leave many columns partially filled or that contain much blank space should be avoided.

11) Figure Legends. Figures are numbered consecutively with Arabic numerals and listed in order rather than one per page. Legends must provide sufficient explanation for the reader to understand the figure independent of the text.

12) Figures.

1) Graphics: Figures should be submitted in different file formats, including TIFF, EPS, JPEG, GIF, high-resolution PDF, and power point format. To ensure the highest print quality, you are required to submit high-resolution images. Electronic images must be prepared according to the following minimum resolutions: Black and white line art 1200 dpi, grayscale art 600 dpi, color art 300 dpi.

2) Colors: All figures will be published in color for online version and in black and white for printed version. Color photographs will be printed at the Editors’ discretion, on the understanding that the authors will bear the cost.

3) Layout: Figures should be submitted in the actual size at which they should appear in the Journal. They may be printed in either single column (80 mm width) or double column (165 mm width) format. The single column format is preferred. The size of text in figures should be 8-10 points, except for single letter markers which may be 12 points. The use of sans serif font such as Helvetica is preferred. Numbers, letters, and symbols used in multi-paneled figures must be consistent. Complex textures and shading to achieve a three dimensional effect should be avoided. To show a pattern, a simple cross-hatch design should be used. Lines should be no thinner than 0.5 point. For a line graph, use standard symbols in the following order of preference: ○, ●, □, ■, D, ▲; x and + should be avoided.

4) Contents: Abbreviations such as Me for CH3, Et for C2H5, and Ph (but not j) for C6H5 are acceptable. Make liberal use of “R and X groups” in equations, schemes, and structure blocks to avoid the repetition of similar structures. Do not repeat a structure; the number alone of an earlier structure can be used if a compound occurs several times. Schemes are numbered with Arabic numerals. Within schemes, structures should be numbered with boldface Arabic numerals, consecutively from left to right, top to bottom, regardless of the order in which the compounds are discussed in the text. Schemes should be footnoted in the manner described below for Tables. It is not necessary to give reagents and conditions in complete detail, since this detail is contained in the Materials and Methods Section. Where needed, numbers such as NMR chemical shifts may be included directly on structural formulas.

13) Chemical Structures. Drawing preferences (preset in the ACS Stylesheet in ChemDraw) are as follows:

1) As drawing settings select:
   - chain angle 120º
   - bond spacing 18% of width
   - fixed length 14.4 pt (0.508 cm, 0.2 in.)
   - bold width 2.0 pt (0.071 cm, 0.0278 in.)
   - line width 0.6 pt (0.021 cm, 0.0084 in.)
   - margin width 1.6 pt (0.056 cm, 0.0222 in.)
   - hash spacing 2.5 pt (0.088 cm, 0.0347 in.)

2) As text settings select:
   - font Arial/Helvetica
   - size 10 pt

3) Under the preferences choose:
   - units points
   - tolerances 5 pixels

4) Under page setup choose:
   - paper US Letter
   - scale 100%

5) Using the ChemDraw ruler or appropriate margin settings, create structure blocks, schemes, and equations having maximum widths of 11.3 cm (one column format) or 23.6 cm (two-column format). Note: if the foregoing preferences are selected as cm values, the ChemDraw ruler is calibrated in cm. ChemDraw graphics will be reduced to 75% during production.

6) Embolden compound numbers, but not atom labels or captions.

7) Authors are urged to use only a single configurational descriptor (heavy line or dashed line, but not both) when defining a stereocenter in a chemical structure. Atoms should be kept outside of rings wherever possible. Rather than rectangular solid and dashed lines, authors should use solid and dashed wedges to indicate configurations, as shown below. Dots at ring junctions intended to represent
hydrogen atoms should not be used. Structures should be drawn in a neat manner ready for direct reproduction, and should not be cluttered or overlapping. Any arrows and numbering used for atoms in figures should not come into contact with bonds or ring systems. See an example of a prepared structure using ChemDraw with the specified preferences below. In molecules containing a chiral biphenyl axis, it is recommended that one of the aromatic rings be drawn in the plane of the paper and the second one be rotated out of the plane of the paper, to reflect the $P$ or $M$ conformation of the biphenyl bond (see below for example).

5. Review of Manuscripts
All manuscripts are first evaluated for their scientific content and significance by the editors and will be subjected to at least two independent reviewers. However, editors reserve the right to reject a manuscript without conducting an in-depth review if they feel that the manuscript is out of the scope or does not meet the minimal acceptance criteria for publication. The manuscript with incorrect format may be declined without further review.

6. Proofs
Authors are responsible for the factual accuracy of their papers. One set of proofs will be supplied for the author to check for typesetting accuracy, to be returned to the publisher within 3 days of receipt. No changes to the original manuscript will be allowed at this stage. In addition, the editors reserve the right to make any necessary correction to a paper prior to publication.

7. Transfer of Copyright
All authors must sign the ‘Transfer of Copyright’ agreement before the article can be published. This transfer agreement enables the Pharmaceutical Society of Korea to protect the copyrighted material for the authors, but does not relinquish the author’s proprietary rights.